CHA Vaccine Research Institute

A261780

KR7261780001

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 15/05/2024 BST			5-day change	1st Jan Change
4,890 ^KRW	+0.72%		-2.00%	-13.45%

01-08	CHA Biotech to Partner with Subsidiary to Advance NK Cell Therapy	MT
2023	Cha Vaccine Research Institute Co., Ltd. announced that it has received KRW 10 billion in funding from EBEST Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.	CI

Cha Vaccine Research Institute Co., Ltd. has filed an IPO.

April 26, 2021 at 05:00 am

Cha Vaccine Research Institute Co., Ltd. has filed an IPO.

Security Name: Shares
Security Type: Common Stock
PriceRange: KRW 13000 to KRW 16000

Transaction Features: ESOP Related Offering

Latest news about CHA Vaccine Research Institute

CHA Biotech to Partner with Subsidiary to Advance NK Cell Therapy	01-08	MT
Cha Vaccine Research Institute Co., Ltd. announced that it has received KRW 10 billion in funding from EBEST Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.	11-16	CI
Cha Vaccine Research Institute Co., Ltd. announced that it expects to receive KRW 10 billion in funding from EBEST Investment & Securities Co., Ltd., Mirae Asset Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.	11-14	CI
Cha Vaccine Research Institute Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
Cha Vaccine Research Institute Co., Ltd. has completed an IPO in the amount of KRW 43.45 billion.	22/10/21	CI
Cha Vaccine Research Institute Co., Ltd. has filed an IPO.	26/04/21	CI

Chart CHA Vaccine Research Institute

Duration

Period

More charts

CHA Vaccine Research Institute Co Ltd is a Korea-based company principally engaged in the vaccines and immunotherapy research business based on based on adjuvant platform technology. The Company is engaged in the research and development (R&D) of premium preventive vaccines, therapeutic vaccines and immunotherapies such as hepatitis B virus (HBV) vaccines, chronic HBV vaccines and others. The Company is also engaged in the vaccines distribution and licensing out services.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CHA VACCINE RESEARCH INSTITUTE	-13.45%	95.9M
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	113B
REGENERON PHARMACEUTICALS, INC.	+10.21%	106B
ARGENX SE	+0.41%	22.27B
BIONTECH SE	-11.90%	22.22B
GENMAB A/S	-5.99%	19.43B
WUXI APPTEC CO., LTD.	-37.36%	17.87B
BEIGENE, LTD.	-5.17%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.52B